Prevalence of Prescription Medication Use Among Non-pregnant Women of Childbearing Age and Pregnant Women in the United States: NHANES, 1999–2006

Maternal and Child Health Journal

Volumn 19, Issue 5, 2015, Pages 1097-1106

  Tinker, Sarah C ^a   Broussard, Cheryl S ^a   Frey, Meghan T ^a,b   Gilboa, Suzanne M ^a  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

Author keywords

Medication; NHANES; Pregnancy; Prescription; Women

Indexed keywords

BRONCHODILATING AGENT; ORAL CONTRACEPTIVE AGENT; PRESCRIPTION DRUG;

ADOLESCENT; ADULT; CLASSIFICATION; COMPARATIVE STUDY; ETHNIC GROUP; FEMALE; HUMAN; NUTRITION; PREGNANCY; PREGNANT WOMAN; PREVALENCE; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; BRONCHODILATOR AGENTS; CONTRACEPTIVES, ORAL; ETHNIC GROUPS; FEMALE; HUMANS; NUTRITION SURVEYS; PREGNANCY; PREGNANT WOMEN; PRESCRIPTION DRUGS; PREVALENCE; SOCIOECONOMIC FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84939607218     PISSN: 10927875     EISSN: 15736628     Source Type: Journal    
DOI: 10.1007/s10995-014-1611-z     Document Type: Article

References (55)

1. Adam, M. P., Polifka, J. E., & Friedman, J. M. (2011). Evolving knowledge of the teratogenicity of medications in human pregnancy. American Journal of Medical Genetics Part C, Seminars in Medical Genetics,157(3), 175–182.
2. Lagoy, C. T., Joshi, N., Cragan, J. D., et al. (2005). Medication use during pregnancy and lactation: An urgent call for public health action. Journal of Women’s Health,14(2), 104–109.
3. Lo, W. Y., & Friedman, J. M. (2002). Teratogenicity of recently introduced medications in human pregnancy. Obstetrics and Gynecology,100(3), 465–473.
4. Mitchell, A. A. (2003). Systematic identification of drugs that cause birth defects—A new opportunity. The New England Journal of Medicine,349(26), 2556–2559.
5. Thorpe, P. G., Gilboa, S. M., Hernandez-Diaz, S., et al. (2013). Medications in the first trimester of pregnancy: Most common exposures and critical gaps in understanding fetal risk. Pharmacoepidemiology and Drug Safety,22(9), 1013–1018.
6. Artama, M., Gissler, M., Malm, H., et al. (2011). Nationwide register-based surveillance system on drugs and pregnancy in Finland 1996–2006. Pharmacoepidemiology and Drug Safety,20(7), 729–738.
7. Bakker, M. K., Jentink, J., Vroom, F., et al. (2006). Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG,113(5), 559–568.
8. Bjorn, A. M., Norgaard, M., Hundborg, H. H., et al. (2011). Use of prescribed drugs among primiparous women: An 11-year population-based study in Denmark. Clinical Epidemiology,3, 149–156.
9. Daw, J. R., Hanley, G. E., Greyson, D. L., et al. (2011). Prescription drug use during pregnancy in developed countries: A systematic review. Pharmacoepidemiology and Drug Safety,20(9), 895–902.
10. Espnes, M. G., Bjorge, T., & Engeland, A. (2011). Comparison of recorded medication use in the Medical Birth Registry of Norway with prescribed medicines registered in the Norwegian Prescription Database. Pharmacoepidemiology and Drug Safety,20(3), 243–248.
11. Stephansson, O., Granath, F., Svensson, T., et al. (2011). Drug use during pregnancy in Sweden—Assessed by the Prescribed Drug Register and the Medical Birth Register. Clinical Epidemiology,3, 43–50.
12. Andrade, S. E., Gurwitz, J. H., Davis, R. L., et al. (2004). Prescription drug use in pregnancy. American Journal of Obstetrics and Gynecology,191(2), 398–407.
13. Mitchell, A. A., Gilboa, S. M., Werler, M. M., et al. (2011). Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. American Journal of Obstetrics and Gynecology,205(1), 51e1–51e8.
14. Werler, M. M., Mitchell, A. A., Hernandez-Diaz, S., et al. (2005). Use of over-the-counter medications during pregnancy. American Journal of Obstetrics and Gynecology,193(3 Pt 1), 771–777.
15. Finer, L. B., & Zolna, M. R. (2014). Shifts in intended and unintended pregnancies in the United States, 2001–2008. American Journal of Public Health,104(Suppl 1), S43–S48.
16. Ayoola, A. B., Nettleman, M. D., Stommel, M., et al. (2010). Time of pregnancy recognition and prenatal care use: A population-based study in the United States. Birth,37(1), 37–43.
17. Sadler, T. W. (2011). Langman’s medical embryology. Baltimore, MD: Wolters Kluwer Health.
18. Kaufman, D. W., Kelly, J. P., Rosenberg, L., et al. (2002). Recent patterns of medication use in the ambulatory adult population of the United States: The Slone survey. The Journal of the American Medical Association,287(3), 337–344.
19. National Center for Health Statistics. (2012). National Health and Nutrition Examination Survey—NHANES 1999–2000. http://www.cdc.gov/nchs/nhanes/nhanes1999-2000/nhanes99_00.htm. Accessed 31 December 2012.
20. National Center for Health Statistics. (2012). National Health and Nutrition Examination Survey—NHANES 2001–2002. http://www.cdc.gov/nchs/nhanes/nhanes2001-2002/nhanes01_02.htm. Accessed 31 December 2012.
21. National Center for Health Statistics. (2012). National Health and Nutrition Examination Survey—NHANES 2003–2004. http://www.cdc.gov/nchs/nhanes/nhanes2003-2004/nhanes03_04.htm. Accessed 31 December 2012.
22. National Center for Health Statistics. (2012). National Health and Nutrition Examination Survey—NHANES 2005–2006. http://www.cdc.gov/nchs/nhanes/nhanes2005-2006/nhanes05_06.htm. Accessed 31 December 2012.
23. Mirel, L. B., Curtin, L. R., Gahche, J., et al. (2009). Characteristics of pregnant women from the 2001–2006 National Health and Nutrition Examination Survey. JSM, 2592–2602.
24. Mitchell, A. A. (2005). Studies of drug-induced birth defects. In B. L. Strom (Ed.), Pharmacoepidemiology. New York, NY: Wiley.
25. Curtin, L. R., Mohadjer, L. K., Dohrmann, S. M., et al. (2012). The National Health and Nutrition Examination Survey: Sample design, 1999–2006. Vital and Heatlh Statistics, 2(155), 24.
26. National Center for Health Statistics. (2013). National Health and Nutrition Examination Survey: 1999–2000 data documentation, codebook, and frequencies—Demographic variables and sample weights (DEMO). http://www.cdc.gov/nchs/nhanes/nhanes1999-2000/DEMO.htm. Accessed 30 August 2013.
27. Mosher, W. D., & Jones, J. (2010). Use of contraception in the United States: 1982–2008. Vital and Health Statistics Series 23, Data from the National Survey of Family Growth,29, 1.
28. Einarson, A., Selby, P., & Koren, G. (2001). Abrupt discontinuation of psychotropic drugs during pregnancy: Fear of teratogenic risk and impact of counselling. Journal of Psychiatry & Neuroscience: JPN,26(1), 44–48.
29. Matsui, D. (2012). Adherence with drug therapy in pregnancy. Obstetrics and Gynecology International,2012, 796590.
30. Olesen, C., Sondergaard, C., Thrane, N., et al. (2001). Do pregnant women report use of dispensed medications? Epidemiology,12(5), 497–501.
31. Morgan, M. A., Cragan, J. D., Goldenberg, R. L., et al. (2010). Management of prescription and nonprescription drug use during pregnancy. Journal of Maternal-Fetal and Neonatal Medicine,23(8), 813–819.
32. Gu, Q., Dillon, C. F., & Burt, V. L. (2010). Prescription drug use continues to increase: U.S. prescription drug data for 2007–2008. NCHS Data Brief,42, 1–8.
33. Salganicoff, A., Ranji, U. R., & Wyn, R. (2005). Women and health care: A national profile: Key findings from the Kaiser women’s health survey. Henry J. Kaiser Family Foundation.
34. Mack, K. A., Jones, C. M., & Paulozzi, L. J. (2013). Vital Signs: Overdoses of prescription opioid pain relievers and other drugs among women—United States, 1999–2010. Morbidity and Mortality Weekly Report,62(26), 537–542.
35. Desai, R. J., Hernandez-Diaz, S., Bateman, B. T., et al. (2014). Increase in prescription opioid use during pregnancy among Medicaid-enrolled women. Obstetrics and Gynecology,123(5), 997–1002.
36. Sauber-Schatz, E. K., Mack, K. A., Diekman, S. T., et al. (2013). Associations between pain clinic density and distributions of opioid pain relievers, drug-related deaths, hospitalizations, emergency department visits, and neonatal abstinence syndrome in Florida. Drug and Alcohol Dependence, 133(1), 161–166.
37. Williams, B. (2013). Drug-dependent at birth: Neonatal abstinence syndrome in Tennessee. Tennessee Medicine: Journal of the Tennessee Medical Association,106(3), 22–26.
38. Broussard, C. S., Rasmussen, S. A., Reefhuis, J., et al. (2011). Maternal treatment with opioid analgesics and risk for birth defects. American Journal of Obstetrics and Gynecology,204(4):314e1–314e11.
39. Centers for Disease Control and Prevention. (2011). National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention.
40. Kwon, H. L., Belanger, K., & Bracken, M. B. (2003). Asthma prevalence among pregnant and childbearing-aged women in the United States: estimates from national health surveys. Annals of Epidemiology,13(5), 317–324.
41. Allan, W. C., Haddow, J. E., Palomaki, G. E., et al. (2000). Maternal thyroid deficiency and pregnancy complications: Implications for population screening. Journal of Medical Screening,7(3), 127–130.
42. Browne, M. L., Rasmussen, S. A., Hoyt, A. T., et al. (2009). Maternal thyroid disease, thyroid medication use, and selected birth defects in the National Birth Defects Prevention Study. Birth Defects Research, Part A: Clinical and Molecular Teratology,85(7), 621–628.
43. Mannisto, T., Mendola, P., Grewal, J., et al. (2013). Thyroid diseases and adverse pregnancy outcomes in a contemporary US cohort. The Journal of Clinical Endocrinology and Metabolism,98(7), 2725–2733.
44. Mannisto, T., Mendola, P., Reddy, U., et al. (2013). Neonatal outcomes and birth weight in pregnancies complicated by maternal thyroid disease. American Journal of Epidemiology,178(5), 731–740.
45. American College of Obstetricians and Gynecologists. (2002). ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 37, August 2002. (Replaces Practice Bulletin Number 32, November 2001). Thyroid disease in pregnancy. Obstetrics and Gynecology,100(2), 387–396.
46. Misra, D. P., Grason, H., & Weisman, C. (2000). An intersection of women’s and perinatal health: The role of chronic conditions. Women’s Health Issues,10(5), 256–267.
47. Namazy, J. A., Murphy, V. E., Powell, H., et al. (2013). Effects of asthma severity, exacerbations and oral corticosteroids on perinatal outcomes. The European Respiratory Journal,41(5), 1082–1090.
48. Vissenberg, R., van den Boogaard, E., van Wely, M., et al. (2012). Treatment of thyroid disorders before conception and in early pregnancy: A systematic review. Human Reproduction Update,18(4), 360–373.
49. Burrow, G. N., Fisher, D. A., & Larsen, P. R. (1994). Maternal and fetal thyroid function. The New England Journal of Medicine,331(16), 1072–1078.
50. Frederiksen, M. C. (2001). Physiologic changes in pregnancy and their effect on drug disposition. Seminars in Perinatology,25(3), 120–123.
51. Goodrum, L. A., Hankins, G. D., Jermain, D., et al. (2003). Conference report: Complex clinical, legal, and ethical issues of pregnant and postpartum women as subjects in clinical trials. Journal of Women’s Health,12(9), 857–867.
52. Dehlendorf, C., Grumbach, K., Vittinghoff, E., et al. (2011). A study of physician recommendations for reversible contraceptive methods using standardized patients. Perspectives on Sexual and Reproductive Health,43(4), 224–229.
53. Ahluwalia, I. B., Mack, K. A., & Mokdad, A. (2005). Report from the CDC. Changes in selected chronic disease-related risks and health conditions for nonpregnant women 18–44 years old BRFSS. Journal of Women’s Health,14(5), 382–386.
54. Schiller, J. S., Ward, B. W., Freeman, G., et al. (2013). Early release of selected estimates based on data from the 2012 National Health Interview Survey. National Center for Health Statistics, 1–115.
55. Broussard, C. S., Frey, M. T., Hernandez-Diaz, S., et al. (2014). Developing a systematic approach to safer medication use during pregnancy: Summary of a Centers for Disease Control and Prevention-convened meeting. American Journal of Obstetrics and Gynecology, 211(3), 208–214e1.